메뉴 건너뛰기




Volumn 14, Issue 6, 2014, Pages 396-404

Trabectedin as a single-agent treatment of advanced breast cancer after anthracycline and taxane treatment: A multicenter, randomized, phase II study comparing 2 administration regimens

Author keywords

Ecteinascidin 743; Objective response rate; Overall survival; Progression free survival; Safety; Time to progression

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTHRACYCLINE; ASPARTATE AMINOTRANSFERASE; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA GLUTAMYLTRANSFERASE; TAXANE DERIVATIVE; TRABECTEDIN; 1,3 DIOXOLANE DERIVATIVE; ANTINEOPLASTIC AGENT; TAXOID; TETRAHYDROISOQUINOLINE DERIVATIVE;

EID: 84910646290     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2014.06.006     Document Type: Article
Times cited : (16)

References (40)
  • 1
    • 0003397692 scopus 로고    scopus 로고
    • Accessed June 16, 2014
    • American Cancer Society. Cancer Facts & Figures 2014. Available at: http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf. Accessed June 16, 2014.
    • Cancer Facts & Figures 2014
  • 2
    • 0041330535 scopus 로고    scopus 로고
    • Yondelis (trabectedin, ET-743): The development of an anticancer agent of marine origin
    • C. van Kesteren, M.M. de Vooght, and L. Lopez-Lazaro Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin Anticancer Drugs 14 2003 487 502
    • (2003) Anticancer Drugs , vol.14 , pp. 487-502
    • Van Kesteren, C.1    De Vooght, M.M.2    Lopez-Lazaro, L.3
  • 3
    • 0032542724 scopus 로고    scopus 로고
    • Mechanism for the catalytic activation of ecteinasacidin 743 and its subsequent alkylation of guanine N2
    • B.M. Moore, F.C. Seaman, and R.T. Wheelhouse Mechanism for the catalytic activation of ecteinasacidin 743 and its subsequent alkylation of guanine N2 J Am Chem Soc 120 1998 2490 2491
    • (1998) J Am Chem Soc , vol.120 , pp. 2490-2491
    • Moore, B.M.1    Seaman, F.C.2    Wheelhouse, R.T.3
  • 4
    • 0033566150 scopus 로고    scopus 로고
    • Ecteinascidin-743: A minor groove alkylator that bends DNA towards the major groove
    • M. Zewail-Foote, and L.H. Hurley Ecteinascidin-743: a minor groove alkylator that bends DNA towards the major groove J Med Chem 42 1999 2493 2497
    • (1999) J Med Chem , vol.42 , pp. 2493-2497
    • Zewail-Foote, M.1    Hurley, L.H.2
  • 5
    • 0029838307 scopus 로고    scopus 로고
    • DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by Ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata
    • Y. Pommier, G. Kohlhagen, and C. Bailly DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by Ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata Biochemistry 35 1996 13303 13309
    • (1996) Biochemistry , vol.35 , pp. 13303-13309
    • Pommier, Y.1    Kohlhagen, G.2    Bailly, C.3
  • 6
    • 0035146702 scopus 로고    scopus 로고
    • Ecteinascidin-743 (ET-743), a natural marine compound with a unique mechanism of action
    • E. Erba, D. Bergamaschi, and L. Bassano Ecteinascidin-743 (ET-743), a natural marine compound with a unique mechanism of action Eur J Cancer 37 2001 97 105
    • (2001) Eur J Cancer , vol.37 , pp. 97-105
    • Erba, E.1    Bergamaschi, D.2    Bassano, L.3
  • 7
    • 0035542848 scopus 로고    scopus 로고
    • Antitumor activity- and gene expression-based profiling of ecteinascidin ET-743 and phthalascidin Pt 650
    • E.J. Martinez, E.J. Corey, and T. Owa Antitumor activity- and gene expression-based profiling of ecteinascidin ET-743 and phthalascidin Pt 650 Chem Biol 8 2001 1151 1160
    • (2001) Chem Biol , vol.8 , pp. 1151-1160
    • Martinez, E.J.1    Corey, E.J.2    Owa, T.3
  • 8
    • 0037096739 scopus 로고    scopus 로고
    • Ecteinascidin-743 inhibits activated but not constitutive transcription
    • D. Friedman, Z. Hu, and E.A. Kolb Ecteinascidin-743 inhibits activated but not constitutive transcription Cancer Res 62 2002 3377 3381
    • (2002) Cancer Res , vol.62 , pp. 3377-3381
    • Friedman, D.1    Hu, Z.2    Kolb, E.A.3
  • 9
    • 17944374027 scopus 로고    scopus 로고
    • Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair
    • Y. Takebayashi, P. Pouquier, and D.B. Zimonjic Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair Nat Med 7 2001 961 966
    • (2001) Nat Med , vol.7 , pp. 961-966
    • Takebayashi, Y.1    Pouquier, P.2    Zimonjic, D.B.3
  • 10
    • 0035874074 scopus 로고    scopus 로고
    • Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways
    • G. Damia, S. Silvestri, and L. Carrassa Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways Int J Cancer 92 2001 583 588
    • (2001) Int J Cancer , vol.92 , pp. 583-588
    • Damia, G.1    Silvestri, S.2    Carrassa, L.3
  • 11
    • 0242559104 scopus 로고    scopus 로고
    • Preclinical and clinical results with the natural marine product ET-743
    • M. D'Incalci, and J. Jimeno Preclinical and clinical results with the natural marine product ET-743 Expert Opin Investig Drugs 12 2003 1 11
    • (2003) Expert Opin Investig Drugs , vol.12 , pp. 1-11
    • D'Incalci, M.1    Jimeno, J.2
  • 12
    • 0032693607 scopus 로고    scopus 로고
    • High antitumor activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer
    • H.R. Hendriks, H.H. Fiebig, and R. Giavazzi High antitumor activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer Ann Oncol 10 1999 1233 1240
    • (1999) Ann Oncol , vol.10 , pp. 1233-1240
    • Hendriks, H.R.1    Fiebig, H.H.2    Giavazzi, R.3
  • 13
    • 0031766324 scopus 로고    scopus 로고
    • In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients
    • E. Izbicka, R. Lawrence, and E. Raymond In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients Ann Oncol 9 1998 981 987
    • (1998) Ann Oncol , vol.9 , pp. 981-987
    • Izbicka, E.1    Lawrence, R.2    Raymond, E.3
  • 14
    • 0034813203 scopus 로고    scopus 로고
    • Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: Identification of ecteinascidin-743 as a potent cytotoxic agent
    • W.W. Li, N. Takahashi, and S. Jhanwar Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent Clin Cancer Res 7 2001 2908 2911
    • (2001) Clin Cancer Res , vol.7 , pp. 2908-2911
    • Li, W.W.1    Takahashi, N.2    Jhanwar, S.3
  • 15
    • 0036895987 scopus 로고    scopus 로고
    • Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells
    • K. Scotlandi, S. Perdichizzi, and M.C. Manara Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells Clin Cancer Res 8 2002 3893 3903
    • (2002) Clin Cancer Res , vol.8 , pp. 3893-3903
    • Scotlandi, K.1    Perdichizzi, S.2    Manara, M.C.3
  • 16
    • 0038380364 scopus 로고    scopus 로고
    • Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743
    • A. Kanzaki, Y. Takebayashi, and X.Q. Ren Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743 Mol Cancer Ther 1 2002 1327 1334
    • (2002) Mol Cancer Ther , vol.1 , pp. 1327-1334
    • Kanzaki, A.1    Takebayashi, Y.2    Ren, X.Q.3
  • 17
    • 0344570127 scopus 로고    scopus 로고
    • Interaction of ET-743 and standard cytotoxic agents against a panel of human tumor cell lines ()
    • ( 3896)
    • H. Barrera, R. Moore, and J. Jimeno Interaction of ET-743 and standard cytotoxic agents against a panel of human tumor cell lines () Proc Am Assoc Cancer Res 40 1999 591 ( 3896)
    • (1999) Proc Am Assoc Cancer Res , vol.40 , pp. 591
    • Barrera, H.1    Moore, R.2    Jimeno, J.3
  • 18
    • 0035281641 scopus 로고    scopus 로고
    • Phase i and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors
    • A. Taamma, J.L. Misset, and M. Riofrio Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors J Clin Oncol 19 2001 1256 1265
    • (2001) J Clin Oncol , vol.19 , pp. 1256-1265
    • Taamma, A.1    Misset, J.L.2    Riofrio, M.3
  • 19
    • 33745259879 scopus 로고    scopus 로고
    • A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer
    • L. Zelek, A. Yovine, and E. Brain A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer Br J Cancer 94 2006 1610 1614
    • (2006) Br J Cancer , vol.94 , pp. 1610-1614
    • Zelek, L.1    Yovine, A.2    Brain, E.3
  • 20
    • 0142121506 scopus 로고    scopus 로고
    • Phase i and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours
    • C. Twelves, K. Hoekman, and A. Bowman Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours Eur J Cancer 39 2003 1842 1851
    • (2003) Eur J Cancer , vol.39 , pp. 1842-1851
    • Twelves, C.1    Hoekman, K.2    Bowman, A.3
  • 21
    • 0141731283 scopus 로고    scopus 로고
    • Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug Yondelis (ET-743) in the rat
    • S. Donald, R.D. Verschoyle, and P. Greaves Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug Yondelis (ET-743) in the rat Cancer Res 63 2003 5902 5908
    • (2003) Cancer Res , vol.63 , pp. 5902-5908
    • Donald, S.1    Verschoyle, R.D.2    Greaves, P.3
  • 22
    • 0036387382 scopus 로고    scopus 로고
    • Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: Associations with clinical characteristics, pathophysiological variables and toxicity
    • T.A. Puchalski, D.P. Ryan, and R. Garcia-Carbonero Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity Cancer Chemother Pharmacol 50 2002 309 319
    • (2002) Cancer Chemother Pharmacol , vol.50 , pp. 309-319
    • Puchalski, T.A.1    Ryan, D.P.2    Garcia-Carbonero, R.3
  • 23
    • 42149132719 scopus 로고    scopus 로고
    • Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment
    • G.J. Fetterly, J.S. Owen, and K. Stuyckens Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment Cancer Chemother Pharmacol 62 2008 135 147
    • (2008) Cancer Chemother Pharmacol , vol.62 , pp. 135-147
    • Fetterly, G.J.1    Owen, J.S.2    Stuyckens, K.3
  • 24
    • 33745161449 scopus 로고    scopus 로고
    • Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma
    • F. Grosso, P. Dileo, and R. Sanfilippo Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma Eur J Cancer 42 2006 1484 1490
    • (2006) Eur J Cancer , vol.42 , pp. 1484-1490
    • Grosso, F.1    Dileo, P.2    Sanfilippo, R.3
  • 25
    • 0024536437 scopus 로고
    • Optimal two-stage designs for phase II clinical trials
    • R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1989 1 10
    • (1989) Control Clin Trials , vol.10 , pp. 1-10
    • Simon, R.1
  • 26
    • 0027965381 scopus 로고
    • Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer
    • K. Porkka, C. Blomqvist, and P. Rissanen Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer J Clin Oncol 12 1994 1639 1647
    • (1994) J Clin Oncol , vol.12 , pp. 1639-1647
    • Porkka, K.1    Blomqvist, C.2    Rissanen, P.3
  • 27
    • 67549088920 scopus 로고    scopus 로고
    • Randomized phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma (L-sarcomas) after failure of prior anthracyclines (A) and ifosfamide ()
    • ( 10060)
    • J.A. Morgan, A. Le Cesne, and S. Chawla Randomized phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma (L-sarcomas) after failure of prior anthracyclines (A) and ifosfamide () J Clin Oncol 25 2007 559s ( 10060)
    • (2007) J Clin Oncol , vol.25 , pp. 559s
    • Morgan, J.A.1    Le Cesne, A.2    Chawla, S.3
  • 28
    • 37049010261 scopus 로고    scopus 로고
    • Trabectedin (T) in relapsed advanced ovarian cancer (ROC): A pooled analysis of three phase II studies ()
    • ( 5579)
    • S. McMeekin, J.M. del Campo, and N. Colombo Trabectedin (T) in relapsed advanced ovarian cancer (ROC): a pooled analysis of three phase II studies () J Clin Oncol 25 2007 293s ( 5579)
    • (2007) J Clin Oncol , vol.25 , pp. 293s
    • McMeekin, S.1    Del Campo, J.M.2    Colombo, N.3
  • 29
    • 0035281734 scopus 로고    scopus 로고
    • Ecteinascidin-743: A marine-derived compound in advanced, pretreated sarcoma patients - Preliminary evidence of activity
    • S. Delaloge, A. Yovine, and A. Taamma Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients - preliminary evidence of activity J Clin Oncol 19 2001 1248 1255
    • (2001) J Clin Oncol , vol.19 , pp. 1248-1255
    • Delaloge, S.1    Yovine, A.2    Taamma, A.3
  • 30
    • 20044372153 scopus 로고    scopus 로고
    • Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial
    • A. Le Cesne, J.Y. Blay, and I. Judson Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial J Clin Oncol 23 2005 576 584
    • (2005) J Clin Oncol , vol.23 , pp. 576-584
    • Le Cesne, A.1    Blay, J.Y.2    Judson, I.3
  • 31
    • 24944460785 scopus 로고    scopus 로고
    • Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: Multicenter phase II and pharmacokinetic study
    • R. Garcia-Carbonera, J.G. Supko, and J. Maki Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study J Clin Oncol 23 2005 5484 5492
    • (2005) J Clin Oncol , vol.23 , pp. 5484-5492
    • Garcia-Carbonera, R.1    Supko, J.G.2    Maki, J.3
  • 32
    • 2342461682 scopus 로고    scopus 로고
    • Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy
    • R. Garcia-Carbonero, J.G. Supko, and J. Manola Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy J Clin Oncol 22 2004 1480 1490
    • (2004) J Clin Oncol , vol.22 , pp. 1480-1490
    • Garcia-Carbonero, R.1    Supko, J.G.2    Manola, J.3
  • 33
    • 1542398698 scopus 로고    scopus 로고
    • Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients
    • A. Yovine, M. Riofrio, and J.Y. Blay Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients J Clin Oncol 22 2004 890 899
    • (2004) J Clin Oncol , vol.22 , pp. 890-899
    • Yovine, A.1    Riofrio, M.2    Blay, J.Y.3
  • 34
    • 0036270843 scopus 로고    scopus 로고
    • ET-743: The US experience in sarcomas of soft tissues
    • G.D. Demetri ET-743: the US experience in sarcomas of soft tissues Anticancer Drugs 13 suppl 1 2002 S7 9
    • (2002) Anticancer Drugs , vol.13 , pp. 7-9
    • Demetri, G.D.1
  • 35
    • 20144377216 scopus 로고    scopus 로고
    • Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails
    • C. Sessa, F. De Braud, and A. Perotti Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails J Clin Oncol 23 2005 1867 1874
    • (2005) J Clin Oncol , vol.23 , pp. 1867-1874
    • Sessa, C.1    De Braud, F.2    Perotti, A.3
  • 36
    • 37049038819 scopus 로고    scopus 로고
    • A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens
    • C.N. Krasner, D.S. McMeekin, and S. Chan A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 2007 1618 1624
    • (2007) Br J Cancer , vol.97 , pp. 1618-1624
    • Krasner, C.N.1    McMeekin, D.S.2    Chan, S.3
  • 37
    • 84882449972 scopus 로고    scopus 로고
    • Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: A retrospective, multicenter study
    • G. Ferrandina, V. Salutari, and B. Vincenzi Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: a retrospective, multicenter study Gynecol Oncol 130 2013 505 510
    • (2013) Gynecol Oncol , vol.130 , pp. 505-510
    • Ferrandina, G.1    Salutari, V.2    Vincenzi, B.3
  • 38
    • 47549083451 scopus 로고    scopus 로고
    • DNA repair functionality as a molecular signature for sensitivity(S)/resistance(R) in sarcoma patients (pts) treated with trabectedin (ET-743, Yondelis) ()
    • Accessed February 1, 2012
    • Schoffski P, Grosso F, Taron M, et al. DNA repair functionality as a molecular signature for sensitivity(S)/resistance(R) in sarcoma patients (pts) treated with trabectedin (ET-743, Yondelis) (). Annual Meeting of the American Association for Cancer Research (AACR) Meeting s 2007 ( 144). Available at: http://www.aacrmeetings.org/cgi/content/meeting-/2007/1-Annual-Meeting/144. Accessed February 1, 2012.
    • (2007) Annual Meeting of the American Association for Cancer Research (AACR) Meetings , Issue.144
    • Schoffski, P.1    Grosso, F.2    Taron, M.3
  • 39
    • 84910655313 scopus 로고    scopus 로고
    • Expression of XPG mRNA and protein as potential biomarker of response to trabectedin in sarcoma patients
    • Accessed September 2, 2014
    • Rosell R, Martinez N, Rodriguez S, et al. Expression of XPG mRNA and protein as potential biomarker of response to trabectedin in sarcoma patients (). Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 2007 ( C127). Available at: http://www.aacrmeetings.org/cgi/gca?allch=&SEARCHID=1&AUTHOR1=Rosell&FULLTEXT=XPG&FIRSTINDEX=0&hits=10&RESULTFORMAT=&gca=aacrmtg%3B2007%2F3-Molecular-Targets-Meeting%2FC127. Accessed September 2, 2014.
    • (2007) Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics , pp. C127
    • Rosell, R.1    Martinez, N.2    Rodriguez, S.3
  • 40
    • 77955491837 scopus 로고    scopus 로고
    • Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer
    • B.J. Monk, T.J. Herzog, and S.B. Kaye Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 2010 3107 3114
    • (2010) J Clin Oncol , vol.28 , pp. 3107-3114
    • Monk, B.J.1    Herzog, T.J.2    Kaye, S.B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.